Pharmacological Treatment of Bipolar Depression

Bipolar Disorder: Clinical and Neurobiological Foundations

Volumn , Issue , 2010, Pages 294-303

  Young, Allan H ^a   Nemeroff, Charles B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute efficacy of quetiapine monotherapy in patients with bipolar I or bipolar II depression; Adjunctive lamotrigine, as treatment for bipolar I depression investigated in Systematic Treatment Enhancement Programme for Bipolar Disorder (STEP BD); Degree of disability associated with bipolar depression episodes; Diagnostic accuracy, intensive scrutiny for presence of manic hypomanic, psychotic or reverse vegetative symptoms in patients; Lamotrigine use, as maintenance treatment in rapid cycling bipolar disorder; Monamine oxidase inhibitors (MAOIs); Olanzapine and olanzapine fluoxetine combination efficacy of olanzapine fluoxetine combination (OFC); Pharmacological treatment of bipolar depression; Sertraline, bupropion and venlafaxine efficacy adjunctive treatment to mood stabilizers; Treatments for management of bipolar I depression

Indexed keywords

EID: 84880540657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470661277.ch23     Document Type: Chapter

References (82)

1. Merikangas, K.R., Akiskal, H.S., Angst, J. et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch. Gen. Psychiatry, 64, 543-552.
2. Perala, J., Suvisaari, J., Saarni, S.I. et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry, 64, 19-28.
3. Prince, M., Patel, V., Saxena, S. et al. (2007) No health without mental health. Lancet, 370, 859-877.
4. Post, R.M., Denicoff, K.D., Leverich, G.S. et al. (2003) Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J. Clin. Psychiatry, 64, 680-690.
5. Judd, L.L., Akiskal, H.S., Schettler, P.J. et al. (2005) Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry, 62, 1322-1330.
6. Michalak, E.E., Murray, G., Young, A.H. and Lam, R.W. (2008) Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs, 22 (5), 389-406.
7. Judd, L.L., Akiskal, H.S., Schettler, P.J. et al. (2002) The longterm natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry, 59, 530-537.
8. Kupka, R.W., Altshuler, L.L., Nolen, W.A. et al. (2007) Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord., 9, 531-535.
9. Angst, J., Angst, F., Gerber-Werder, R. and Gamma, A. (2005) Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch. Suicide Res., 9 (3), 279-300.
10. Vieta, E., Colom, F., Corbella, B. et al. (2001) Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disord., 3, 253-258.
11. Keller, M.B. (2006) Prevalence and impact of comorbid anxiety and bipolar disorder. J. Clin. Psychiatry, 67 (Suppl. 1), 5-7.
12. Perlis, R.H. (2005) Misdiagnosis of bipolar disorder. Am. J. Manag. Care, 11, S271-S274.
13. Pollack, L.E., Cramer, R.D. and Varner, R.V. (2000) Psychosocial functioning of people with substance abuse and bipolar disorders. Subst. Abus., 21, 193-203.
14. Hirschfeld, R.M., Lewis, L. and Vornik, L.A. (2003) Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry, 64, 161-174.
15. Calabrese, J.R., Kasper, S., Johnson, G. et al. (2004) International Consensus Group on bipolar I depression treatment guidelines. J. Clin. Psychiatry, 65, 569-579.
16. Calabrese, J.R., Kasper, S., Johnson, G. et al. (2010) International Consensus Group on bipolar depression treatment guidelines (Updated and Revised). J. Clin. Psychiatry (In Press).
17. Srisurapanont, M., Yatham, L.N. and Zis, A.P. (1995) Treatment of acute bipolar depression: a review of the literature. Can. J. Psychiatry, 40, 533-544.
18. Young, A.H., McElroy, S., Chang, W. et al. (2008) A doubleblind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I) Poster presented at the International Society for Bipolar Disorders, Delhi and Agra, India, 27-30 January, 2008.
19. Prien, R.F., Klett, C.J. and Caffey, E.M. Jr (1974) Lithium prophylaxis in recurrent affective illness. Am. J. Psychiatry, 131, 198-203.
20. Prien, R.F., Klett, C.J. and Caffey, E.M. Jr (1973) Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch. Gen. Psychiatry, 29, 420-425.
21. Geddes, J.R., Burgess, S., Hawton, K. et al. (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry, 161, 217-222.
22. Smith, L.A., Cornelius, V., Warnock, A. et al. (2007) Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord., 9, 394-412.
23. Baldessarini, R.J. and Tondo, L. (2000) Does lithium treatment still work? Evidence of stable responses over three decades. Arch. Gen. Psychiatry, 57, 187-190.
24. Calabrese, J.R., Bowden, C.L., Sachs, G.S. et al. (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry, 60, 79-88.
25. Calabrese, J.R., Huffman, R.F., White, R.L. et al. (2008) Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord., 10, 323-333.
26. Geddes, J., Huffman, R.F., Paksa, W. et al. (2007) Lamotrigine for acute treatment of bipolar depression: individual patient data meta-analysis of 5 randomised, placebo-controlled trials. Bipolar Disord., 9 (s1), 42.
27. Geddes, J., Calabrese, J.R. and Goodwin, G.M. (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry., 194, 4-9.
28. Bowden, C.L., Calabrese, J.R., Sachs, G. et al. (2003)Aplacebocontrolled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry, 60, 392-400.
29. Calabrese, J.R., Bowden, C.L., Sachs, G.S. et al. (2003) A placebo-controlled 18-month trial of lamotrigine and lithiummaintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry, 64, 1013-1024.
30. Goodwin, G.M., Bowden, C.L., Calabrese, J.R. et al. (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry, 65, 432-441.
31. Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R. et al. (2006) Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry, 163, 210-216.
32. van der Loos, M., Nolen, W. and Vieta, E.,on behalf of all members of the LamLit Study Group (2006) Lamotrigine as add-on to lithium in bipolar depression. Poster P268 presented at the Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006.
33. Licht, R.W. 2008. Lamotrigine versus lithium in prophylaxis of bipolar disorder: a randomised study mimicking clinical practice. Bipolar Disord., 10 (Suppl. 1), 27.
34. Davis, L.L., Bartolucci, A. and Petty, F. (2005) Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord., 85, 259-266.
35. Ghaemi, S.N., Gilmer, W.S., Goldberg, J.F. et al. (2007) Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J. Clin. Psychiatry, 68, 1840-1844.
36. Post, R.M., Uhde, T.W., Roy-Byrne, P.P. and Joffe, R.T. (1986) Antidepressant effects of carbamazepine. Am. J. Psychiatry, 143, 29-34.
37. Calabrese, J.R., Keck, P.E. Jr, Macfadden, W. et al. (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry, 162, 1351-1360.
38. Thase, M.E., Macfadden, W., Weisler, R.H. et al. (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol., 26, 600-609.
39. McElroy, S., Young, A.H., Carlsson, A. et al. (2008) Doubleblind, randomized, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Poster presented at the International Society for Bipolar Disorders, Delhi and Agra, India, 27-30 January, 2008.
40. Suppes, T., Liu, S., Paulsson, B. and Brecher, M. (2007) Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a North American placebo-controlled, randomized multicenter trial. Poster presented at the 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, Florida, USA, 9-13 December, 2007.
41. Vieta, E., Eggens, I., Persson, I. et al. (2007) Efficacy and safety of quetiapine in combination with lithium or divalproex as maintenance treatment for bipolar I disorder. Poster presented at the 20th European College of Neuropsychopharmacology Congress, Vienna, Austria, 13-17 October, 2007.
42. Brown, E.B., McElroy, S.L., Keck, P.E. Jr et al. (2006)A7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry, 67, 1025-1033.
43. Tohen, M., Sanger, T.M., McElroy, S.L. et al. (1999) Olanzapine versus placebo in the treatment of acute mania. Am. J. Psychiatry, 156, 702-709.
44. Keck, P.E. Jr, Corya, S.A., Altshuler, L.L. et al. (2005) Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J. Clin. Psychiatry, 66, 611-616.
45. Brown, E.B., Dunner, D.L., Adams, D.H. et al. (2006) Olanzapine/ fluoxetine combination versus lamotrigine in the longtermtreatment of bipolar I depression. Poster presented at the 2nd Biennial Conference of the International Society for Bipolar Disorders, Edinburgh, UK, 2-4 August, 2006.
46. Gijsman, H.J., Geddes, J.R., Rendell, J.M. et al. (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry, 161, 1537-1547.
47. Sachs, G.S., Nierenberg, A., Calabrese, J.R. et al. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med., 356, 1711-1722.
48. Nemeroff, C.B., Evans, D.L., Gyulai, L. et al. (2001) Doubleblind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry, 158, 906-912.
49. Young, L.T., Joffe, R.T., Robb, J.C. et al. (2000) Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression.Am. J. Psychiatry, 157, 124-126.
50. Cohn, J.B., Collins, G., Ashbrook, E. and Wernicke, J.F. (1989) A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol., 4, 313-322.
51. Post, R.M., Altshuler, L.L., Leverich, G.S. et al. (2006) Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry, 189, 124-131.
52. Vieta, E., Martinez-Arán, A., Goikdea, J.M. et al. (2002) A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry, 63 (6), 508-512.
53. Sachs, G.S., Lafer, B., Stoll, A.L. et al. (1994) A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry, 55 (9), 391-393.
54. Fogelson, D.L., Bystritsky, A. and Pasnau, R. (1992) Bupropion in the treatment of bipolar disorders: the same old story? J. Clin. Psychiatry, 53 (12), 443-446.
55. Himmelhoch, J.M., Fuchs, C.Z. and Symons, B.J. (1982) A double-blind study of tranylcypromine treatment of major anergic depression. J.Nerv.Ment. Dis., 170 (10), 628-634.
56. Himmelhoch, J.M., Thase, M.E., Mallinger, A.G. and Houck, P. (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am. J. Psychiatry, 148 (7), 910-916.
57. Thase, M.E., Mallinger, A.G., McKnight, D. and Himmelhoch, J.M. (1992) Treatment of imipramine-resistant recurrent depression. IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am. J. Psychiatry, 149 (2), 195-198.
58. Frye, M.A., Grunze, H., Suppes, T. et al. (2007) A placebocontrolled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am. J. Psychiatry, 164, 1242-1249.
59. Goldberg, J.F., Burdick, K.E. and Endick, C.J. (2004) Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry, 161, 564-566.
60. Gallagher, P., Malik, N., Newham, J. et al. (2008) Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst. Rev (1), CD005168.
61. Young, A.H., Gallagher, P., Watson, S. et al. (2004) Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmcology, 29 (8), 1538-1545.
62. Gallagher, P., Watson, S., Smith, M.S. et al. (2005) Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol. Psychiatry, 57 (2), 155-161.
63. Gallagher, P., Watson, S., Elizabeth Dye, C. et al. (2008) Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia. J. Psychiatr. Res., 42 (12), 1037-1041.
64. Frangou, S., Lewis, M. and McCrone, P. (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry, 188, 46-50.
65. Thase, M.E., Jonas, A., Khan, A. et al. (2008) Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol., 28, 13-20.
66. Simon, J.S. and Nemeroff, C.B. (2005) Ariprazole augmentation of antidepressants for the treatment of partially responding and non-responding patients with major depressive disorder. J. Clin. Psychiat., 66, 1216-1220.
67. Marcus, R.N., McQuade, R.D., Carson, W.H. et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 28 (2), 156-165.
68. Vieta, E. and Suppes, T. (2008) Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord., 10, 163-178.
69. Coryell, W., Endicott, J., Andreasen, N. and Keller, M. (1985) Bipolar I, bipolar II, and nonbipolar major depression among the relatives of affectively ill probands. Am. J. Psychiatry, 142, 817-821.
70. Vieta, E., Gasto, C., Otero, A. et al. (1997) Differential features between bipolar I and bipolar II disorder. Compr. Psychiatry, 38, 98-101.
71. Benazzi, F. (1999)Acomparison of the age of onset of bipolar I and bipolar II outpatients. J. Affect. Disord., 54, 249-253.
72. Judd, L.L., Akiskal, H.S., Schettler, P.J. et al. (2003) The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J. Affect. Disord., 73, 19-32.
73. Suppes, T., Hirschfeld, R.M., Vieta, E. et al. (2008) Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J. Biol. Psychiatry, 9, 198-211.
74. Zarate, C.A. Jr, Payne, J.L., Singh, J. et al. (2004) Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry, 56, 54-60.
75. Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006) SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J. Affect. Disord., 92, 205-214.
76. Calabrese, J.R., Shelton, M.D., Rapport, D.J. et al. (2005) A 20- month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am. J. Psychiatry, 162, 2152-2161.
77. Calabrese, J.R., Suppes, T., Bowden, C.L. et al. (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J. Clin. Psychiatry, 61, 841-850.
78. Vieta, E., Calabrese, J.R., Goikolea, J.M. et al. (2007) Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord., 9, 413-425.
79. Bauer, M.S. and Whybrow, P.C. (1990) Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch. Gen. Psychiatry, 47 (5), 435-440.
80. McElroy, S.L., Dessain, E.C., Pope, H.G. Jr et al. (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry, 52 (10), 411-414.
81. Suppes, T., McElroy, S.L., Gilbert, J. et al. (1992) Clozapine in the treatment of dyxphoric mania. Biol. Psychiatry, 32 (3), 270-280.
82. Suppes, T., McElroy, S.L., Gilbert, J. et al. (1992) Clozapine in the treatment of dyxphoric mania. Biol. Psychiatry, 32 (3), 270-280.